Search | Clinical Trials Finder

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Atrial Flow Regulator, Sham Comparator; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Phoenix, Arizona • New York, New York

Conditions: Shigella
Interventions: ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU; Biological · Other
Lead sponsor: Eveliqure Biotechnologies GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sexually Transmitted Diseases
Interventions: NgG 12.5 µg investigational vaccine, NgG 25 µg investigational vaccine, NgG 50 µg investigational vaccine, Placebo; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1,009 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts + 4 more

Conditions: Osteoarthritis of the Knee
Interventions: 4 mL injection of Ampion, 4 mL Injection of Placebo; Biological · Drug
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: HIV-1-infection
Interventions: Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo; Drug
Lead sponsor: ST Pharm Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Los Angeles, California • Ft. Pierce, Florida • Miami, Florida + 9 more

Conditions: Tobacco Use Disorder, Smoking
Interventions: Ariva Silver Wintergreen, Ariva Wintergreen; Other
Lead sponsor: Star Scientific, Inc; Industry
Eligibility: 23 Years to 72 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Martinsburg, West Virginia

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 24
States / cities: Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more

Conditions: Alzheimer's Disease
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Huntington's Disease
Interventions: Placebo, Dimebon; Other · Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 29 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Stroke
Interventions: SUN13837, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Mobile, Alabama • Encinita, California • Oceanside, California + 29 more

Conditions: Migraine, Headaches
Interventions: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more

Conditions: Severe Sepsis
Interventions: Talactoferrin alfa, Placebo; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more

Conditions: Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Interventions: Placebo Matching Mitapivat, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • La Jolla, California • Oakland, California + 7 more

Conditions: Hypothalamic Obesity
Interventions: LB54640, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more

Conditions: Ulcerative Colitis
Interventions: AEB071, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Mobile, Alabama • Mesa, Arizona • Topeka, Kansas + 4 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching Placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Conditions: Sickle Cell Disease
Interventions: TRF-1101, Placebo; Drug
Lead sponsor: TRF Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more

Conditions: Campylobacter Infections
Interventions: LMN-101, Placebo; Biological · Drug
Lead sponsor: Lumen Bioscience, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: Placebo, Docetaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 24
States / cities: Tucson, Arizona • Berkeley, California • Montebello, California + 17 more

Conditions: Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions: Extended release niacin, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more

Search by objective public record fields.

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

TRF-1101 Assessment in Sickle Cell Disease

LMN-101 in a Campylobacter Human Challenge Model

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation